Skip to main content
. 2022 Apr 5;20:159. doi: 10.1186/s12967-022-03359-x

Table 2.

Clinical outcomes of the entire population to checkpoint inhibitors immunotherapy

Clinical outcomes Patients, n (%)
ORR 114 (41.9)
SD 40 (14.7)
DCR 154 (56.6)
PD 118 (43.4)
PFS, median [IQR] 10 [6–15]
OS, median [IQR] 29 [22–43]

ORR overall response rate, SD stable disease lasting 6 months or more, DCR disease control rate (major responses + SD lasting 6 months or more), PD progressive disease (non-responders + SD lasting less than 6 months), PFS progression free survival, OS overall survival